UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2025
Commission
File Number: 001-41677
CytoMed
Therapeutics Limited
(Registrant’s
Name)
1
Commonwealth Lane
#08-22
Singapore
149544
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
On
August 28, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release, announcing that in addition to adult
peripheral blood mononuclear cell-derived therapeutics, the Company has successfully expanded clinical-scale natural killer (“NK”)
cells from cord blood units, and intends to re-organize
and streamline its group structure to create a new cord blood-derived biotech.
A
copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
Financial
Statements and Exhibits.
The
following exhibits are being filed herewith:
Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release dated August 28, 2025, titled “CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
CytoMed
Therapeutics Limited |
| |
|
|
| Date:
August 28, 2025 |
By: |
/s/
Choo Chee Kong |
| |
Name: |
Choo
Chee Kong |
| |
Title: |
Chairman
and Director |
